Merck opens 2 process development centres in US, China

Merck opens 2 process development centres in US, China

9:58 AM, 11th January 2017
Merck logo

DARMSTADT, GERMANY: The Merck Group expands its global end-to-end bio development centres to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and industry-leading technological expertise.

The expansion, which includes the opening of two new process development centres in the US and China, follows the commercial success of Merck’s bio development centre in Martillac, France.

The two new units will be located in close proximity to customers in the Shanghai and Boston metropolitan areas. Each will provide a full range of process development capabilities and services. This includes cell line development services, both upstream and downstream process development, as well as non-GMP clinical production.

Merck’s bio development centre in Martillac, France, is a fully operational single-use, GMP facility for manufacturing clinical stage batches. Equipped with a full suite of Merck technologies, including the 2000 litre single-use Mobius bioreactor, Martillac offers biopharma companies a complete solution to support their clinical development programs.

Merck’s end-to-end offering delivers important benefits and addresses key challenges for biopharmaceutical companies at all stages of molecule development and commercialization in any geography. In addition to the Mobius bioreactor, the end-to-end portfolio includes solutions such as Lynx CDR, Viresolve Process Area Modules, Pellicon and Centinel Intelligence Virus Defense.

Early-stage companies with limited resources and infrastructure benefit from a partner with strong expertise and experience developing processes and GMP clinical manufacturing to help accelerate early clinical development programs. Companies in more advanced stages need to overcome the challenges of moving from late phase clinical development into commercial manufacturing, accelerating the availability of affordable life-enhancing drugs. With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer of an entire process to a new location.

“We are seeing an increasing global demand for end-to-end process development solutions and Merck offers a one-stop shop for biopharma customers,” said Udit Batra, member of the Merck executive board and CEO, Life Science.

“This expansion reinforces our position as the premier supplier of all process development and clinical stage manufacturing solutions, materials and services needed for the production of biologics. This is a strategic, high-potential investment for Merck specifically designed to meet customer needs on three continents,” added Batra.

© Worldofchemicals news

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Sabic launches new polymer foam grades

SITTARD, THE NETHERLANDS: Sabic has unveiled two new dedicated foam grades, Sabic LDPE HP2024JDF and HP2024NDF, for the Middle East, African (MEAF) an ...

Read more
Fine art: painting tricks of 19th century revealed

PARIS, FRANCE: To paint quickly while creating brilliant texture and volume effects artists relied on the development of innovative gels. All the rage ...

Read more
Some catalysts give their own oxygen for reactions: Study

MASSACHUSETTS, US: Chemical reactions that release oxygen in the presence of a catalyst, known as oxygen evolution reactions, are a vital part of the ...

Read more
New reliable method to capture carbon from ambient air

OAK RIDGE, US: Scientists at the Department of Energy’s Oak Ridge National Laboratory have found a simple, reliable process to capture carbon di ...

Read more
Total to acquire Tullow’s Uganda stake for $900 million

PARIS, FRANCE: Total SA and Tullow Oil have entered into a package agreement under which Total will acquire an additional 21.57 percent interest from ...

Read more
Merck, CLEARink sign agreement on display technology

DARMSTADT, GERMANY: The Merck Group has signed a comprehensive materials development agreement with CLEARink Displays Inc, aiming to bring CLEARink&rs ...

Read more
Copyright © 2017. Kimberlite Softwares Pvt. Ltd., India. All rights reserved.
World of Chemicals.